

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Hayashi N.	Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.	J Gastroenterol.	46 (11)	1335-1343	2011 Nov
Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M.	Genetic Variation of the IL-28B Promoter Affecting Gene Expression.	PLoS One.	6 (10)	e26620	2011 Oct
Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Yatsuhashi H, Izumi N.	Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.	Antivir Ther.	17 (1)	35-43	2011 Oct
Matsushima-Nishiwaki R, Adachi S, Yoshioka T, Yasuda E, Yamagishi Y, Matsuura J, Muko M, Iwamura R, Noda T, Toyoda H, Kaneoka Y, Okano Y, Kumada T, Kozawa O.	Suppression by heat shock protein 20 of hepatocellular carcinoma cell proliferation via inhibition of the mitogen-activated protein kinases and AKT pathways.	J Cell Biochem.	112 (11)	3430-3439	2011 Nov
Ebinuma H, Saito H, Komuta M, Ojio K, Wakabayashi K, Usui S, Chu PS, Umeda R, Ishibashi Y, Takayama T, Kikuchi M,	Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with Fibroscan (R).	J Gastroenterol.	46 (10)	1238-1248	2011 Oct

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nakamoto N, Yamagishi Y, Kanai T, Ohkuma K, Sakamoto M , Hibi T.					
Suzuki H, Murata K, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, Kudo M, Mizokami M , Sakamoto A.	Phenotype-dependent production of des-gamma-carboxy prothrombin in hepatocellular carcinoma.	J Gastroenterol.	46 (10)	1219-1 229	2011 Oct
Nakamura I, Tanaka Y , Ochiai K, Moriyasu F, Mizokami M , Imawari M.	Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses.	Hepatology Res.	41 (9)	838-84 5	2011 Sep
Sugiyama M, Inui A, Shin-I T, Komatsu H, Mukaide M, Masaki N, Murata K, Ito K, Nakanishi M, Fujisawa T, Mizokami M .	Easy-to-use phylogenetic analysis system for hepatitis B virus infection.	Hepatology Res.	41 (10)	936-94 5	2011 Oct
Kuno A , Ikehara Y, Tanaka Y , Saito K, Ito K, Tsuruno C, Nagai S, Takahama Y, Mizokami M , Hirabayashi J, Narimatsu H .	LecT-Hepa: A triplex lectin-antibody sandwich immuneassay for estimating the progression dynamics of liver fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine.	Clin Chim Acta.	412 (19-2 0)	1767-1 772	2011 Sep
Furui Y, Hoshi Y, Murata K, Ito K, Suzuki K, Uchida S, Satake M, Mizokami M , Tadokoro K.	Prevalence of Amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors.	J Med Virol.	83 (11)	1924-1 929	2011 Nov

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T.	Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan.	BMC Res Note.	4	341	2011 Sep
Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Toyoda H, Kumada T, Goto H.	Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.	Liver Int.	31 (9)	1359-1 365	2011 Sep
Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsushashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M.	Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.	Hum Mol Genet.	20 (17)	3507-3 516	2011 Sep
Toyoda H, Kumada T, Kaneoka Y, Maeda A.	Amino acid substitutions in the hepatitis C virus core region are associated with post-operative recurrence and survival of patients with HCV genotype 1b-associated hepatocellular carcinoma.	Ann Surg.	254 (2)	326-33 2	2011 Aug
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Fukui H, Hijioka T, Katayama K,	Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.	J Gastroenterol.	46 (8)	1031-1 037	2011 Aug

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Hosui A, Miyagi T, Ishida H, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.					
Kumada T, Toyoda H, Arakawa T, Sone Y, Fujimori M, Ogawa S, Ishikawa T.	Evolution of Hypointense Hepatocellular Nodules Observed Only in the Hepatobiliary Phase of Gadoxetate Disodium-Enhanced MRI.	Am J Roentogenol	197	58-63	2011 Jul
Toyoda H, Kumada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F.	Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.	J Med Virol.	83 (9)	1559-1564	2011 Jul
Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Kuzuya T, Itakura J, Nakanishi H, Takahashi Y, Kurosaki M, Asahina Y, Enomoto N, Sakamoto M, Izumi N.	Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation.	Oncology.	80	278-288	2011 Jul
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Kaneko A, Hagiwara	The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in	J Gastroenterol.	46 (7)	944-952	2011 Jul

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
H, Mita E, Ito T, Nagase T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Imai Y, Kato M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.	Japan.				
Sa-Nguanmoo P, Tanaka Y , Ratanakorn P, Sugiyama M, Murakami S, Payungporn S, Sommanustweechai A, Mizokami M , Poovorawan Y.	Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes.	Virus Res.	158 (1-2)	209-21 5	2011 Jun
Ninomiya M, Ueno Y, Shimosegawa T.	PBC: Animal Models of Cholangiopathies and Possible Endogenous Viral Infections.	Int J Hepatol.	2012	Article ID:649 290, 6 pages	2011 Jun
Makino Y, Imai Y, Fukuda K, Seki Y, Kogita S, Sawai Y, Igura T, Kurokawa M, Takamura M.	Sonazoid-enhanced ultrasonography for the diagnosis of an intrapancreatic accessory spleen: a case report.	J Clin Ultrasound.	39 (6)	344-34 7	2011 Jul
Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue	Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma.	Clin Gastroenter ol Hepatol.	9 (5)	428-43 3	2011 May

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
T; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan.					
Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, Satomura S.	Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL.	Cancer Sci.	102 (5)	1025-1031	2011 May
Toyoda H, Kumada T, Tada T, Kawaguchi T, Murakami Y, Matsuda F.	Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.	J Med Virol.	83 (7)	1203-1211	2011 Jul
Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsunami H, Orito E, Kani S, Tanaka Y, Mizokami M.	The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.	J Clin Microbiol.	49 (5)	1853-1860	2011 May
Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S,	Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial.	Hepatol Res.	41 (6)	505-511	2011 Jun

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Joh T, Mizokami M.					
Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, Nishida N, Tokunaga K, Mizokami M, Izumi N.	Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.	Antivir Ther.	16	685-694	2011 May
Onomoto K, Morimoto S, Kawaguchi T, Toyoda H, Tanaka M, Kuroda M, Uno K, Kumada T, Matsuda F, Shimotohno K, Fujita T, Murakami Y.	Dysregulation of IFN System Can Lead to Poor Response to Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis C.	PLoS ONE.	6 (5)	e19799	2011 May
Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima H, Maehara Y.	Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era.	World J Surg.	35 (5)	1072-1084	2011 May
Toshima T, Shirabe K, Takeishi K, Motomura T, Mano Y, Uchiyama H, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y.	New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver.	J Gastroenterol.	46 (5)	705-711	2011 May
Tatematsu K, Tanaka Y, Sugiyama M, Sudoh M, Mizokami M.	Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B	J Med Virol.	83 (4)	587-593	2011 Apr

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
	virus replication.				
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Kaytayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.	J Hepatol.	54 (4)	604-611	2011 Apr
Toyoda H, Kumada T, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Arakawa T, Fujimori M, Niinomi T, Ando N, Yasuda S, Sakai K, Kimura J.	High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in hepatitis C virus in patients infected with HCV genotype 1b.	J Gastroenterol.	46 (4)	501-509	2011 Apr
Kumada T, Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamoti A, Tada T, Tanaka J, Yoshizawa H.	Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus.	J Gastroenterol.	46 (4)	536-544	2011 Apr
Kanathezath B, Mizokami M, Stanislaus S, Hounshell C, Neumayr L, Guo H, Hearst JE, Walters MC,	Improved engraftment with minimal graft-versus-host disease after major histocompatibility complex-mismatched cord blood	Exp Biol Med (Maywood).	236 (4)	492-504	2011 Apr

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kuypers FA.	transplantation with photochemically treated donor lymphocytes.				

総説

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T; the Osaka Liver Forum.	Post-treatment levels of α -fetoprotein predict Incidence of hepatocellular carcinoma after interferon therapy.	Clin Gastroenterol Hepatol.	In press.		2013 Dec
Mizokami M.	Discovery of critical host factor, IL-28B, associated with response to HCV treatment.	J Gastroenterol Hepatol.	27 (3)	425-429	2012 Mar

総説 (和文)

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
豊田 秀徳、熊田 卓.	HCV 治療後発癌例の解析 (C 型肝炎治療 2014:経口抗ウイルス薬時代の到来, HCV 駆除後肝発癌の対策).	肝胆膵.	67 (6)	1035-1039	2013 Dec
髭 修平、木村 睦海、荒川 智宏、小関 至、狩野 吉康、豊田 成司.	肝線維化の定量的測定 (検査値の読み方 連載).	臨床消化器内科.	28 (13)	1783-1788	2013 Dec
多田 俊史、熊田 卓、豊田 秀徳.	超高齢肝細胞癌患者に対する治療法の選択と予後 -後期高齢者との	The Liver Cancer	5 (4)	268-272	2013 Dec

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
	比較検討-	Journal.			
山本 健太、熊田 卓、桐山 勢生、谷川 誠、久永康宏、豊田 秀徳、金森 明、多田 俊史、北畠 秀介、長谷川 綾平、伊藤 隆徳、安藤 祐資、颯田 祐介、田中 達也、曾根 康博、福里 利夫.	肝細胞癌と鑑別が困難であった reactive lymphoid hyperplasia の 1 例.	肝臓.	54 (11)	755-76 4	2013 Nov
多田 俊史、熊田 卓、豊田 秀徳.	C 型肝硬変例における分岐鎖アミノ酸製剤と肝発癌との関連 -Propensity score 分析を用いた検討-	消化と吸収.	35 (3)	290-29 4	2013 Jul
松田 厚志、久野 敦、成松 久、監修：第 62 回日本医学検査学会記念誌編集委員会.	グライコプロテオミクスによる臨床糖鎖腫瘍マーカー開発 -グライコムからグライコプロテオームへ.	検査診断学への展望 -臨床検査指針：測定とデータ判読のポイント-			2013 May
熊田 卓、多田 俊史、金森 明、豊田 秀徳、乙部 克彦、川島 望、今吉 由美、竹島 賢治.	肝腫瘍の造影超音波診断：鑑別診断 (CEUS Trend View 2013 造影超音波検査の有用性と適応のひろがり-肝腫瘍、乳腺腫瘍診断を中心に：他の領域への臨床応用の可能性も含めて-).	INNERVISION.	28 (3)	6-10	2013 Feb
安藤 直人、熊田 卓、多田 俊史.	高齢 C 型肝炎患者の肝脂肪癌サーベイランスにおける注意点 -性差による検討-	日本消化器がん検診学会雑誌.	51 (1)	55-65	2013 Jan
土谷 薫、泉 並木.	II.肝臓 10.肝癌の画像診断.	Annual Review 消化器.	2013	148-15 7	2013 Jan
村田 一素、溝上 雅史.	II.肝臓 3.肝炎・肝癌の遺伝子研究.	Annual Review 消化器.	2013		2013 Jan

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
多田 俊史、熊田 卓、桐山 勢生、谷川 誠、豊田 秀徳、久永 康宏、金森 明、曾根 康博、小川 定信.	大垣市民病院における EOB-MRI の肝細胞相で検出される乏血性結節の自然経過.	肝胆膵画像.	14 (4) 増刊号	345-350	2012 Jun
熊田 卓、豊田 秀徳、多田 俊史、金森 明、竹島 賢治、乙部 克彦.	4-2 造影超音波診断 (症例編) 肝細胞癌以外の肝腫瘍典型例.	Medical Technology.	別冊	43-58	2012 Jun
貴田岡 正史、熊田 卓、松田 康雄、飯島 尋子、小川 眞広、工藤 信樹、小原 和史、紺野 啓、高倉 玲奈、西田 睦、南 康範、森 秀明、山田 昌彦.	肝腫瘍の超音波診断基準.	超音波医学.	39 巻 3 号	317-326	2012 Jun
多田 俊史、熊田 卓、桐山 勢生、谷川 誠、豊田 秀徳、久永 康宏、金森 明、新家 卓郎、安東 直人、坂井 圭介、安田 諭、木村 純、安藤 祐資、山本 健太.	B 型肝炎に対する核酸アナログ投与例の長期予後 (特集 II B 型肝炎の抗ウイルス療法の進歩と耐性).	消化器内科.	54 (5)	608-613	2012 May
熊田 卓.	肝機能性画像の幹細胞癌診断における役割.	西部 肝臓フォーラム'11 記録集.	2011 巻	205-217	2012 Mar
多田 俊史、熊田 卓、豊田 秀徳.	消化器癌のの見逃しを防ぐ-早期発見・適切な治療のための診断の実際 肝臓癌.	消化器の臨床.	15 (1)	75-81	2012 Feb
Mizokami M.	Discovery of critical host factor, IL-28B, associated with response to HCV treatment.	J Gastroenterol Hepatol.	27 (3)	425-429	2012 Mar
豊田 秀徳、熊田 卓.	HCV 治療後発癌 (特集 C 型肝炎のすべて 2012 HCV と発癌).	肝胆膵.	63 (6)	1009-1014	2011 Dec
久野 敦、池原 譲、成松 久.	グライコプロテオミクスを基軸とした腫瘍マーカー開発技術 (特集 分子腫瘍マーカー: 治療標的と経過指標として).	月刊カレントセラピー (ライフメディコム).	29 (12)	56-60	2011 Dec

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
多田 俊史、熊田 卓、桐山 勢生、谷川 誠、久永康宏、豊田 秀徳、金森 明.	混合型肝癌の臨床・生化学的特徴 (特集 混合型肝癌および胆管形質を示す肝細胞癌:肝ステム細胞のインパクト).	肝胆膵.	63 (4)	573-582	2011 Oct
坂井 圭介、熊田 卓、豊田 秀徳、桐山 勢生、谷川 誠、久永康宏、金森 明、多田 俊史、新家 卓郎、安東 直人、安田 諭、安藤 祐資、山本 健太、木村 純.	肝発癌を視野に入れた B 型肝炎の治療戦略 (特集 II B 型肝炎に対する新治療戦略).	消化器内科.	53 (3)	326-330	2011 Sep
多田 俊史、熊田 卓、桐山 勢生、谷川 誠、豊田 秀徳、久永康宏、金森 明、曾根 康博、小川 定信.	Dynamic MRI による治療効果判定 (特集 肝細胞癌の化学療法-分子標的治療の進歩と効果判定 各論, 肝細胞癌の化学療法の治療効果判定).	肝胆膵画像.	13 (6)	619-626	2011 Sep
熊田 卓、豊田 秀徳、多田 俊史.	早期肝細胞癌の治療の開始時期について (特集 早期肝細胞癌:病理と画像の interplay).	肝臓.	52 (7)	441-448	2011 Aug
熊田 卓、豊田 秀徳、多田 俊史.	高齢者 C 型肝炎では ALT 低値、血小板高値でも発癌する (Session 3 C 型肝炎).	肝炎・肝癌の新しい診断と治療・第 28 回犬山シンポジウム記録集.		125-130	2011 Jun
竹島 賢治、高橋 健一、乙部 克彦、加藤 廣正、今吉 由美、川島 望、坂野 信也、熊田 卓、豊田 秀徳、多田 俊史、安東 直人.	結節型肝細胞癌の B-モード所見および造影超音波による染影パターンと肉眼所見の対比 (肝疾患における最新の超音波診断 第 29 回超音波ドプラ研究会臨床研究集, 主題演題 肝癌の精密診断・肉眼型・分化度・進展度診断).	Rad Fan.	9 (6)	66-68	2011 May

IV.研究成果の刊行物・別刷

A novel serum marker, glycosylated *Wisteria floribunda* agglutinin-positive Mac-2 binding protein (WFA⁺-M2BP), for assessing liver fibrosis

Takeo Toshima · Ken Shirabe · Toru Ikegami · Tomoharu Yoshizumi ·
Atsushi Kuno · Akira Togayachi · Masanori Gotoh · Hisashi Narimatsu ·
Masaaki Korenaga · Masashi Mizokami · Akihito Nishie · Shinichi Aishima ·
Yoshihiko Maehara

Received: 1 November 2013 / Accepted: 7 February 2014
© Springer Japan 2014

Abstract

Background Recently, a novel marker, hyperglycosylated *Wisteria floribunda* agglutinin-positive Mac-2 binding protein (WFA⁺-M2BP), was developed for liver fibrosis using the glycan “sugar chain”-based immunoassay; however, the feasibility of WFA⁺-M2BP for assessing liver fibrosis has not been proven with clinical samples of hepatitis.

Methods Serum WFA⁺-M2BP values were evaluated in 200 patients with chronic liver disease who underwent histological examination of liver fibrosis. The diagnostic

accuracy of WFA⁺-M2BP values was compared with various fibrosis markers, such as ultrasound based-virtual touch tissue quantification (VTTQ), magnetic resonance imaging based-liver-to-major psoas muscle intensity ratio (LMR), and serum markers, including hyaluronic acid, type 4 collagen, and aspartate transaminase to platelet ratio index (APRI).

Results Serum WFA⁺-M2BP levels in patients with fibrosis grades F0, F1, F2, F3, and F4 had cutoff indices 1.62, 1.82, 3.02, 3.32, and 3.67, respectively, and there were significant differences between fibrosis stages F1 and F2, and between F2 and F3 ($P < 0.01$). The area under the receiver operating characteristic curves for the diagnosis of fibrosis ($F \geq 3$) using serum WFA⁺-M2BP values (0.812) was almost comparable to that using VTTQ examination (0.814), but was superior to the other surrogate markers, including LMR index (0.766), APRI (0.694), hyaluronic acid (0.683), and type 4 collagen (0.625) ($P < 0.01$ each). **Conclusions** Serum WFA⁺-M2BP values based on a glycan-based immunoassay is an accurate, reliable, and reproducible method for the assessment of liver fibrosis. This approach could be clinically feasible for evaluation of beneficial therapy through the quantification of liver fibrosis in hepatitis patients if this measurement application is commercially realized.

Electronic supplementary material The online version of this article (doi:10.1007/s00535-014-0946-y) contains supplementary material, which is available to authorized users.

T. Toshima · K. Shirabe (✉) · T. Ikegami · T. Yoshizumi ·
Y. Maehara

Department of Surgery and Science, Graduate School of Medical
Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku,
Fukuoka 812-8582, Japan
e-mail: kshirabe@surg2.med.kyushu-u.ac.jp

A. Kuno · A. Togayachi · M. Gotoh · H. Narimatsu
Research Center for Medical Glycoscience (RCMG), National
Institute of Advanced Industrial Science and Technology
(AIST), Tsukuba 305-8568, Japan

M. Korenaga · M. Mizokami
The Research Center for Hepatitis and Immunology,
National Center for Global Health and Medicine,
Ichikawa 272-8516, Japan

A. Nishie
Department of Clinical Radiology, Graduate School of Medical
Sciences, Kyushu University, Fukuoka 812-8582, Japan

S. Aishima
Department of Anatomic Pathology, Graduate School of Medical
Sciences, Kyushu University, Fukuoka 812-8582, Japan

Keywords Liver fibrosis · Chronic hepatitis · M2BP ·
Mac-2 binding protein · VTTQ · Fibrosis marker

Abbreviations

ALT	Alanine aminotransferase
APRI	Aspartate transaminase-to-platelet ratio index
ARFI	Acoustic radiation force impulse
AST	Aspartate aminotransferase

COI	Cutoff index
Gd-EOB-DTPA	Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
HBsAg	Hepatitis B virus surface antigen
HBV	Hepatitis B virus
HCV	Hepatitis C virus
HCVAb	Hepatitis C virus antibody
LMR	Liver-to-major psoas muscle intensity ratio
m/s	Meters per second
MRI	Magnetic resonance imaging
NPV	Negative predictive value
nonBnonC	Negative for hepatitis B virus surface antigen and hepatitis C virus antibody
PBC	Primary biliary cirrhosis
PPV	Positive predictive value
ROC	Receiver operating characteristic
VTTQ	Virtual Touch™ Tissue Quantification
WFA ⁺ -M2BP	<i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein

Introduction

The management of chronic liver disease depends on the degree of liver fibrosis. Therefore, assessment of the degree of liver fibrosis is important for choosing a therapeutic strategy and for determining the prognosis [1, 2]. Liver biopsy is the gold standard method for evaluating the degree of liver fibrosis [3]. However, the invasiveness of liver biopsy, its potential for life-threatening complications, and sampling errors place a heavy burden on those patients with hepatitis who require follow-up [4–6]. Therefore, many reports have demonstrated non-invasive examination methods for assessing the degree of liver fibrosis, which might be alternatives to liver biopsy, such as new serum markers and transient elastography [7–9]. However, none of these studies developed a definitive method.

Recently, a novel marker for liver fibrosis was developed using the glycan “sugar chain”-based immunoassay, and the FastLec-Hepa system was used to determine serum values of “sweet-doughnut” hyperglycosylated *Wisteria floribunda* agglutinin-positive Mac-2 binding protein (WFA⁺-M2BP) for the assessment of liver fibrosis [10, 11]. This unique technical approach supported by multiple lectin-assisted glycan profiling may be applicable to the development pipeline for a wide variety of glycodiagnostic tools. However, the feasibility of WFA⁺-M2BP for assessing liver fibrosis has not been proven with clinical samples of hepatitis.

A method based on acoustic radiation force impulse (ARFI) imaging, with virtual touch tissue quantification (VTTQ), has been developed to evaluate liver fibrosis.

VTTQ measurements can be performed during observation of a particular liver lesion with an ultrasonic probe, and measurements are reproducible compared with transient elastography [12, 13]. For assessment of liver imaging, we have developed magnetic resonance imaging (MRI) using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) enhancement to assess liver function, which may vary inversely for liver fibrosis with the passing grade [14]. Indeed, the increase in rate of liver-to-major psoas muscle intensity ratio (LMR) in the hepatobiliary phase compared with the precontrast image is best correlated with the degree of liver fibrosis, and significantly decreases as liver fibrosis progresses (F0–F4).

This study aimed to compare the diagnostic accuracy of serum WFA⁺-M2BP values using the area under receiver operating characteristic (ROC) curves. The diagnostic performance of serum WFA⁺-M2BP values was compared with validated surrogate fibrosis markers, including VTTQ, the MRI-LMR index, and serum markers, such as hyaluronic acid, type 4 collagen, and the aspartate amino-transferase-to-platelet ratio index (APRI).

Methods

Patients

The study cohort consisted of 200 adults, including 40 healthy volunteers and 160 patients with or without hepatitis, who underwent hepatectomy or living donor liver transplantation, and whose serum WFA⁺-M2BP values and liver stiffness by VTTQ were measured at Kyushu University Hospital. Serum samples of inferior quality, which had the potential of measurement errors, such as those with hemolysis, milky fluid, or protein aggregation, were excluded [15]. Of the 160 patients, 106 were positive for antibody to hepatitis C virus (HCVAb), 21 were positive for hepatitis B virus (HBV) surface antigen (HBsAg), 12 had hepatitis due to alcohol, and 21 were negative for HBsAg and HCVAb. The study protocol conformed to the ethical guidelines of the 1975 Helsinki Declaration and was approved by our institutional review board.

Liver histology and quantification of liver fibrosis

All liver specimens were obtained by surgical resection and were fixed in formalin, embedded in paraffin wax, and stained with hematoxylin and eosin and Masson’s trichrome. The fibrosis staging in all surgical specimens was determined independently by two pathologists who did not know the VTTQ values. In case of discrepancies, histological sections were simultaneously reviewed using a multi-pipe microscope to reach a consensus. Fibrosis was

staged on a scale of 0–4 according to the METAVIR classification [18], with F0 indicating no fibrosis; F1, enlarged, fibrotic portal tracts; F2, periportal or portal-portal septa but intact architecture; F3, fibrosis with architectural distortion but no obvious cirrhosis; and F4, probable or definite cirrhosis.

Direct measurement of serum Mac-2 binding protein

The method of assessment of WFA⁺-M2BP was as follows [10, 11]. A glycan-based immunoassay, FastLec-Hepa, was developed as a simple and accurate system to automatically detect a unique fibrosis-related glyco-alteration in serum hyperglycosylated WFA⁺-M2BP. Briefly, the *Wisteria floribunda* agglutinin (WFA)-antibody immunoassay using the HISCL-2000i bedside clinical chemistry analyzer was developed to measure WFA⁺-M2BP values. These values were successfully adjusted every reaction condition during the automatic assay, and heat pretreatment of the serum was avoided to ensure binding avidity and a fast association rate within just 17 min. The measured values of WFA⁺-M2BP conjugated to WFA were indexed with the obtained values using the following equation:

$$\text{Cutoff index (COI)} = \frac{([\text{WFA}^+ - \text{M2BP}]_{\text{sample}} - [\text{WFA}^+ - \text{M2BP}]_{\text{NC}})}{([\text{WFA}^+ - \text{M2BP}]_{\text{PC}} - [\text{WFA}^+ - \text{M2BP}]_{\text{NC}})}$$

$[\text{WFA}^+ - \text{M2BP}]_{\text{sample}}$, WFA⁺-M2BP count of serum sample (PC, positive control; NC, negative control) [10, 11].

VTTQ and ARFI

The VTTQ system was installed on an ACUSON model S2000 ultrasound system (Siemens Medical Solutions, Inc., Ultrasound Division, Issaquah, WA, USA). The operators were surgeons trained by Siemens Medical Solutions, Inc. The VTTQ system uses an acoustic push pulse to generate shear waves, which pass through the liver parenchyma orthogonally to the acoustic push pulse, through a user-placed region of interest. When detection pulses interact with a passing shear wave, they reveal the wave's location at a specific time, allowing calculation of the shear wave speed. This absolute numerical value is related to the stiffness of the tissue within the region of interest [16, 17], and the results are expressed in meters per second (m/s). For each patient, seven successful measurements were performed several days before surgical operations during which histological specimens were obtained. The measurement of VTTQ in the right lobe of the liver was performed by placing the ultrasonic probe on the right intercostal space at a depth from 2 to 4 cm [9]. The median value of all measurements and the standard deviation of all

right and left VTTQ measurements for each patient were considered for analysis.

Analysis of the MRI-LMR index

The analysis system of the LMR in MRI using Gd-EOB-DTPA enhancement was as follows [14]. Briefly, the signal intensities were measured by placing as large a region of interest as possible on the left and right lobes of the liver parenchyma and major psoas muscle, avoiding vessels, tumors and artifacts, and one slice without significant artifacts for the precontrast image and hepatobiliary phase was selected. The increase in rate of the LMR in the hepatobiliary phase compared with the precontrast image was calculated using the following equation:

$$\frac{(\text{LMR in the hepatobiliary phase} - \text{LMR on the precontrast image})}{\text{LMR on the precontrast image}}$$

[14].

Surrogate serum markers

For all patients, blood samples were obtained on the same day that the VTTQ examination was performed, and they were examined in the same laboratory. The following parameters were determined: hyaluronic acid levels, type 4 collagen, platelet count, aspartate aminotransferase (AST) levels, alanine aminotransferase (ALT) levels, ICG-R15, and the APRI. The APRI was calculated as follows: AST level (per upper limit of normal; 33 U/L) \times 100/platelet count (10^9 /L) [18, 19].

Statistical analysis

Differences between quantitative variables for paired samples were analyzed using a nonparametric test (Wilcoxon rank sum test with Bonferroni's adjustment). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of optimal cutoff values of liver surrogate fibrosis markers for the diagnosis of liver fibrosis were calculated as described [18, 19]. In addition, the diagnostic value of liver stiffness for predicting significant liver fibrosis (F1–F3) and cirrhosis (F4) was assessed by calculating the areas under the ROC curves. The ROC curve is a plot of sensitivity versus 1-specificity for all possible cutoff values. The most commonly used index of accuracy is the area under the ROC curve, where values close to 1.0 indicate high diagnostic accuracy, and 0.5 indicates a test of no diagnostic value. The optimal liver stiffness cutoff values used for the diagnosis of significant fibrosis and cirrhosis were selected based on the sensitivity, specificity, PPV, and NPV [18–20]. Statistical analysis of the differences between

the areas under the ROC curves was based on the theory of generalized U-statistics [21]. All of the differences were considered statistically significant at $P < 0.05$.

Results

Patients and liver specimens

Subject characteristics are summarized in Supplementary Table 1. The mean age of the 200 subjects (135 men and 65 women) was 64 ± 20 years. The 200 enrolled adults consisted of 40 healthy volunteers and 160 patients with or without hepatitis; of the latter, 106 were positive for HCVAb, 21 were positive for HBsAg, 12 had hepatitis due to alcohol, and 21 were negative for HBsAg and HCVAb (nonBnonC). Of the 200 surgical liver specimens, 84 had fibrosis grade F0; 45 were F1, 21 were F2, 16 were F3, and 34 were F4.

Liver fibrosis assessed by WFA⁺-M2BP values

Figure 1 shows box plots of serum WFA⁺-M2BP values for each fibrosis stage. Serum WFA⁺-M2BP values measured by the glycan-based immunoassay ranged from 0.22 to 8.69 (COI). WFA⁺-M2BP levels in patients with fibrosis grades F0 ($n = 84$), F1 ($n = 45$), F2 ($n = 21$), F3 ($n = 16$), and F4 ($n = 34$) had COIs of 1.62, 1.82, 3.02, 3.32, and 3.67, respectively. There were significant differences between fibrosis stages F1 and F2 ($P < 0.01$), and between fibrosis stages F2 and F3 ($P < 0.01$) (Fig. 1).

Correlation of WFA⁺-M2BP values with VTTQ, the LMR index, and serum markers of liver fibrosis

The log of WFA⁺-M2BP correlated with VTTQ results, a significant indicator of liver stiffness as liver fibrosis ($P = 0.0001$) (Fig. 2a). Log WFA⁺-M2BP values were also inversely related with the LMR index, a significant indicator of liver function that varies inversely with liver fibrosis ($P = 0.0001$) (Fig. 2b), as well as with type 4 collagen concentrations ($P = 0.0080$) (Fig. 2c) and the APRI ($P = 0.0001$) (Fig. 2d), but not with hyaluronic acid (Fig. 2e) and ICG-R15 concentrations (Fig. 2f).

APRI, aspartate transaminase-to-platelet ratio index; LMR, liver-to-major psoas muscle intensity ratio; VTTQ, Virtual Touch™ Tissue Quantification; WFA⁺-M2BP, *Wisteria floribunda* agglutinin-positive Mac-2 binding protein.

Diagnostic capability of WFA⁺-M2BP values for each type of liver fibrosis

The areas under the ROC curve for the diagnosis of types of fibrosis F1, F2, F3, and F4 with serum WFA⁺-M2BP values





Fig. 1 Box-and-whisker plot of serum WFA⁺-M2BP values for each fibrosis stage. The *tops* and *bottoms* of the boxes represent the first and third quartiles, respectively, with the *height* of the box represents the interquartile range, covering 50 % of the values. The *line* through the middle of each box represents the median. The *error bars* show the minimum and maximum values (range). Significant correlations were found between the stage of fibrosis and serum WFA⁺-M2BP values, and there were significant correlations between fibrosis stages F1 and F2 ($P < 0.01$) and between fibrosis stages F2 and F3 ($P < 0.01$). *Asterisk* Statistically significant by the Wilcoxon rank sum test with Bonferroni's adjustment; $P < 0.01$. WFA⁺-M2BP, *Wisteria floribunda* agglutinin-positive Mac-2 binding protein

were 0.686, 0.820, 0.817, and 0.806, respectively (Fig. 3). The optimal cutoff values were 1.00 m/s for $F \geq 1$, 1.86 m/s for $F \geq 2$, 2.21 m/s for $F \geq 3$, and 2.64 m/s for $F \geq 4$ (Table 1). The sensitivity of the serum WFA⁺-M2BP cutoffs for fibrosis grades $F \geq 1$, $F \geq 2$, $F \geq 3$, and $F \geq 4$ was 84.6, 84.7, 88.2, and 82.4 %, whereas the specificity was 47.6, 74.4, 78.7, and 71.9 %, respectively. The sensitivity of VTTQ cutoffs for these fibrosis grades was 81.9, 70.4, 72.6, and 82.4 %, respectively, while the specificity was 70.2, 82.2, 83.3, and 79.5 %, respectively (Table 1, Supplementary Table 2). Thus, WFA⁺-M2BP cutoffs were more sensitive, but less specific, in predicting liver fibrosis in each grade than the VTTQ cutoffs.

Comparison of WFA⁺-M2BP with other indicators for the diagnosis of fibrosis stage ≥ 3

We compared the area under the ROC curves of VTTQ, the LMR index, and serum markers (APRI, hyaluronic acid, and type 4 collagen) with that of WFA⁺-M2BP values. The cutoff values were determined, as described above. The area under the ROC curves for the diagnosis of fibrosis ($F \geq 3$) using serum WFA⁺-M2BP values (0.812) was comparable to that using VTTQ examination (0.814), but was significantly superior to the other surrogate markers, including LMR index (0.766), APRI (0.694), hyaluronic acid (0.683), and type 4 collagen (0.625) ($P = 0.0001$ each; Fig. 4). Serum WFA⁺-M2BP, VTTQ, LMR index, APRI, hyaluronic acid

Fig. 2 Correlation of WFA⁺-M2BP values with VTTQ, LMR index, and the other serum markers. The log of WFA⁺-M2BP correlated with VTTQ results, a significant indicator of liver stiffness as liver fibrosis ($P = 0.0001$) (a). Log WFA⁺-M2BP values were also inversely related with the LMR index, a significant indicator of liver function that varies inversely with liver fibrosis ($P = 0.0001$) (b), as well as with type 4 collagen concentrations ($P = 0.0080$) (c) and the APRI ($P = 0.0001$) (d), but not with hyaluronic acid (e) and ICG-R15 concentrations (f). APRI aspartate transaminase-to-platelet ratio index, LMR liver-to-major psoas muscle intensity ratio, VTTQ Virtual Touch™ Tissue Quantification, WFA⁺-M2BP *Wisteria floribunda* agglutinin-positive Mac-2 binding protein



concentration, and type 4 collagen concentration cutoffs had sensitivities for fibrosis grades $F \geq 3$ of 88.2, 72.6, 52.9, 66.7, 85.1, and 88.1 %, respectively; specificities of 78.7, 83.3, 78.7, 78.9, 40.8, and 40.5 %, respectively; PPVs of 58.9 %, 60.0 %/ 48.2, 59.6, 34.5, and 33.0 %, respectively; and NPVs of 94.5, 89.9, 83.4, 83.5, 96.2, and 91.1 %, respectively (Table 2).

The areas under the ROC curves for the diagnosis of fibrosis ($F \geq 4$) were comparable for serum WFA⁺-M2BP (0.806) and VTTQ (0.827), but significantly superior to the other surrogate markers, including LMR index (0.776), APRI (0.673), hyaluronic acid (0.657), and type 4 collagen (0.632) ($P = 0.0001$ each; Supplementary Figure 1 and Supplementary Table 3).

Diagnostic capability of WFA⁺-M2BP values for liver fibrosis in each groups

The area under the ROC curves for the diagnosis of fibrosis ($F \geq 3$) using serum WFA⁺-M2BP values was 0.797 in the

107 patients positive for HCVAb and 0.822 in the 21 patients negative for HBsAg and HCVAb, but was insufficient (0.620) in the 21 patients positive for HBsAg. The sensitivity, specificity, PPV, and NPV for the fibrosis grades $\geq F3$ in these three sets of patients using the serum WFA⁺-M2BP cutoff were 96.7 %/100.0 %/61.5 %, 63.6 %/73.3 %/87.5 %, 50.9 %/60.05/88.9 %, and 98.0 %/100.0 %/58.3 %, respectively.

Discussion

This is the first report to quantify liver fibrosis in a large population using serum WFA⁺-M2BP values by the glycan-based immunoassay, FastLec-Hepa, which was developed as a simple and accurate system for automatically detecting unique fibrosis-related glyco-alterations. The accuracy of WFA⁺-M2BP values for diagnosing liver




Fig. 3 Diagnostic ability of serum WFA⁺-M2BP values to assess stages of liver fibrosis. The areas under the ROC curves of serum WFA⁺-M2BP values for diagnosing liver fibrosis were **a** 0.698 for grade $F \geq 1$, **b** 0.837 for grade $F \geq 2$, **c** 0.812 for grade $F \geq 3$, and **d** 0.795 for grade $F \geq 4$. ROC receiver operating characteristic, WFA⁺-M2BP *Wisteria floribunda* agglutinin-positive Mac-2 binding protein

Table 1 WFA⁺-M2BP values for assessment of liver fibrosis

	Optimal cutoff (COI)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
$F \geq 1$	1.00	84.6	47.6	69.2	69.0
$F \geq 2$	1.86	84.7	74.4	64.9	89.7
$F \geq 3$	2.21	88.2	78.7	58.9	94.5
$F \geq 4$	2.64	82.4	71.9	37.3	95.2

Optimal cutoff points gave the highest total sensitivity and specificity
 APRI Aspartate transaminase-to-platelet ratio index, COI cutoff index, WFA⁺-M2BP *Wisteria floribunda* agglutinin-positive Mac-2 binding protein, *m/s* meters per second NPV negative predictive value, PPV positive predictive value, VTTQ Virtual Touch™ Tissue Quantification

fibrosis grade $F \geq 3$, measured as sensitivity, specificity, PPV, and NPV, was better than that for other surrogate markers, such as the MRI-LMR index and other serum markers of liver fibrosis, including levels of hyaluronic acid, type 4 collagen, and the APRI. WFA⁺-M2BP could be an alternative non-invasive serum marker for liver biopsy for assessing liver fibrosis.

No reports have demonstrated the feasibility of serum WFA⁺-M2BP values as a predictor of liver fibrosis, and the function of WFA⁺-M2BP is unclear. Iacobelli et al. [22] identified WFA⁺-M2BP in 1986 as a tumor-associated antigen and detected it in culture media using a monoclonal antibody from CG-5 breast cancer cell lines. WFA⁺-M2BP

is a highly glycosylated secreted protein, a plant hemagglutinin Mac-2 (galectin-3) ligand, and has 90-kDa subunits, hence, the name 90K. WFA⁺-M2BP mainly mediates cell-to-cell and cell-to-matrix interactions, and is involved in cell proliferation and angiogenesis [23–25] by inducing the expression of cytokines, such as interleukin (IL)-1, IL-2, and IL-6 [23–25]. Indeed, endogenous WFA⁺-M2BP ligands laminin, fibronectin, and lysosome-associated membrane protein [26, 27], and enhances cell adhesion and the extracellular matrix to promote fibrosis. Therefore, expression of WFA⁺-M2BP levels may be proportional to the degree of liver fibrosis in patients with chronic liver diseases.

In our study, serum WFA⁺-M2BP values had better diagnostic ability for assessment of liver fibrosis than the other serum markers, such as the APRI, hyaluronic acid, and type 4 collagen, as evaluated by the area under the ROC curves. For diagnosing fibrosis stage ≥ 3 , the specificity and PPV using serum WFA⁺-M2BP were 78.7 and 58.9 %, respectively compared with 78.7 and 48.2 %, respectively, using APRI; 40.8 and 34.5 %, respectively, using hyaluronic acid, and 40.5 and 33.0 %, respectively, using type 4 collagen cutoffs. These results suggest that examination of serum WFA⁺-M2BP values is the most accurate diagnostic tool for liver fibrosis among the serum markers investigated in this study.

The diagnostic significance of surrogate markers in liver fibrosis has been evaluated distinguishing F3 from F2 fibrosis. The clinical significance of distinguishing F3 from F2 fibrosis has been widely accepted in the follow-up of patients with viral hepatitis, and also has been linked with hepatocarcinogenesis [28, 29]. The annual carcinogenesis rate was reported to be correlated with the stage of liver fibrosis in the study of 2,890 patients with hepatitis [28]. The annual incidence of hepatocellular carcinoma in patients with severe liver fibrosis of grade F3 is high (5.3 %), whereas the incidence in those with moderate liver fibrosis of grade F2 is low (1.9 %) [29]. Therefore, fibrotic change is closely correlated with hepatocarcinogenesis in patients with viral hepatitis, and it is critically important to distinguish between liver fibrosis of grades F3 and F2, which was the cause of the favorable point for the serum WFA⁺-M2BP examination superior to the other markers in our study. In addition, we found that the measurement time for our glycan-based immunoassay was only 17 min, which has practical implications. However, a limitation is that its measurement was just applied by the glycan “sugar chain”-based immunoassay, the FastLec-Hepa system, which is currently only available in a few selected institutions. Commercial application of this system is a primary goal for evaluation of a clinically beneficial therapy through quantification of liver fibrosis in hepatitis patients. This study, however, had one important limitation, in that




Fig. 4 Comparison of WFA⁺-M2BP with other indicators for the diagnosis of fibrosis stage $F \geq 3$ by areas under the receiver operating curves (ROC). The areas under the ROC curves for the diagnosis of grade $F \geq 3$ fibrosis were a 0.812 for serum WFA⁺-M2BP, b 0.814 for VTTQ, c 0.766 for LMR index, d 0.694 for APRI, e 0.683 for

hyaluronic acid, and f 0.625 for type 4 collagen. APRI aspartate transaminase-to-platelet ratio index, LMR liver-to-major psoas muscle intensity ratio, ROC receiver operating characteristic, VTTQ Virtual Touch™ Tissue Quantification, WFA⁺-M2BP *Wisteria floribunda* agglutinin-positive Mac-2 binding protein

Table 2 Diagnostic performance of indicators predicting liver fibrosis ($F \geq 3$)

	Optimal cutoff	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
WFA ⁺ -M2BP	2.21 (COI)	88.2	78.7	58.9	94.5
VTTQ	1.77 (m/s)	72.6	83.3	60.0	89.9
LMR index	1.15	66.7	78.9	59.6	83.5
APRI	3.33	52.9	78.7	48.2	83.4
Hyaluronic acid	58.0 (ng/mL)	85.1	40.8	34.5	96.2
Type 4 collagen	125.0 (ng/mL)	88.1	40.5	33.0	91.1

Optimal cutoff points gave the highest total sensitivity and specificity

APRI Aspartate transaminase-to-platelet ratio index, COI cutoff index, WFA⁺-M2BP *Wisteria floribunda* agglutinin-positive Mac-2 binding protein, m/s meters per second, NPV negative predictive value, PPV positive predictive value, VTTQ Virtual Touch™ Tissue Quantification

the number of patients with a fibrosis score of F3 was relatively low. Most patients who underwent hepatectomy had Child-Pugh grade A liver function and fibrosis scores of F0, F1, and F2, whereas most patients who underwent living donor liver transplantation had liver cirrhosis (F4). Accumulation of additional liver specimens by surgical resection may be necessary.

We have previously demonstrated that VTTQ values are correlated with liver fibrosis [9, 12, 13]. Compared with VTTQ, serum WFA⁺-M2BP values were almost equal for predicting liver fibrosis $\geq F3$, with similar areas under the ROC curves (0.812 vs 0.814) and similar sensitivity (88.2 vs 72.6 %), and specificity (78.7 vs 83.3 %). However, this VTTQ method has some limitations compared with serum WFA⁺-M2BP values. First, the diagnostic accuracy of

VTTQ values in the right and left lobes of the liver was significantly different; VTTQ values in the right lobe were more accurate for diagnosing liver fibrosis than those in the left lobe, as evaluated by the area under the ROC curves and the standard deviations of each VTTQ value [9]. The other limitation is the lower diagnostic accuracy of VTTQ values in fatty liver compared with other types of hepatitis for predicting liver fibrosis [30]. Therefore, the diagnostic accuracy for assessment of liver fibrosis needs to be compared between serum WFA⁺-M2BP and VTTQ values in these marginal clinical cases in the future. In addition, the VTTQ system installed on the ultrasound system by Siemens Medical Solutions is expensive [15–17]. Therefore, it may have the clinical significance of the WFA⁺-M2BP assessment for the medical economy to assess the